Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis - Seite 2
European Patent Application No. 18717135.0 “Anti CCL24 (eotaxin2) Antibodies for Use in the Treatment of Hepatic Diseases” has a grant date of March 20, 2024.
In combination with the five families of CM-101 composition of matter and use patents that are either issued or pending in major territories worldwide, these new patents are expected to provide protection of CM-101 across a number of indications until 2038, with the possibility of up to five years extension upon market approval. CM-101 has been granted Orphan Drug designation in the U.S. and the E.U. and the FDA has awarded CM-101 Fast Track designation for the treatment of PSC in adults.
About CM-101
CM-101 is a monoclonal antibody that neutralizes CCL24, a soluble protein that helps drive the inflammatory and fibrotic pathways central to many fibro-inflammatory diseases. CCL24's role as a
therapeutic target has been validated in extensive clinical and nonclinical studies and proof-of-concept for CM-101 has been demonstrated in multiple animal and patient sample studies. CM-101 was
safe and well tolerated in four Phase 1 and Phase 2 clinical trials. Data from a completed Phase 2a liver fibrosis trial in nonalcoholic steatohepatitis (NASH) patients showed consistent, positive
improvements in key inflammatory and fibrogenesis-related biomarkers, including several that may serve as a potential bridge to activity in PSC. Patient enrollment has been completed in an ongoing
CM-101 Phase 2 PSC trial and a readout of topline data is expected midyear 2024.
Lesen Sie auch
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential
to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver
fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with
topline data expected midyear 2024. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready. For more information about Chemomab, visit chemomab.com.